Amicus Therapeutics (NASDAQ:FOLD) Price Target Raised to $20.00

Amicus Therapeutics (NASDAQ:FOLD) had its price objective lifted by HC Wainwright from $18.00 to $20.00 in a research report issued on Tuesday, Briefing.com Automated Import reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 108.99% from the stock’s current price.

FOLD has been the topic of several other research reports. Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 price target on the stock in a report on Monday, November 4th. Cowen set a $31.00 price objective on Amicus Therapeutics and gave the company a “buy” rating in a report on Thursday, October 10th. BidaskClub raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Amicus Therapeutics in a report on Thursday, October 17th. Finally, ValuEngine cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $17.97.

Shares of FOLD stock traded up $0.22 on Tuesday, hitting $9.57. 3,073,900 shares of the stock were exchanged, compared to its average volume of 2,514,296. The firm’s 50 day moving average is $8.40 and its two-hundred day moving average is $10.76. Amicus Therapeutics has a one year low of $7.11 and a one year high of $14.61. The firm has a market capitalization of $2.43 billion, a PE ratio of -7.20 and a beta of 1.58. The company has a current ratio of 6.20, a quick ratio of 6.97 and a debt-to-equity ratio of 0.36.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.08. Amicus Therapeutics had a negative return on equity of 62.61% and a negative net margin of 216.02%. The firm had revenue of $48.80 million for the quarter, compared to analysts’ expectations of $48.05 million. During the same quarter last year, the firm posted ($0.84) EPS. The company’s revenue was up 136.9% compared to the same quarter last year. On average, sell-side analysts expect that Amicus Therapeutics will post -1.27 earnings per share for the current year.

In related news, CEO John F. Crowley sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $10.05, for a total transaction of $201,000.00. Following the transaction, the chief executive officer now directly owns 770,194 shares of the company’s stock, valued at approximately $7,740,449.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO John F. Crowley sold 14,500 shares of the firm’s stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $8.01, for a total value of $116,145.00. Following the transaction, the chief executive officer now directly owns 735,694 shares in the company, valued at $5,892,908.94. The disclosure for this sale can be found here. Over the last three months, insiders have sold 54,500 shares of company stock worth $497,545. 2.50% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in FOLD. First Trust Advisors LP purchased a new position in Amicus Therapeutics in the 1st quarter worth approximately $635,000. Fox Run Management L.L.C. purchased a new position in Amicus Therapeutics in the 2nd quarter worth approximately $204,000. Strs Ohio increased its stake in Amicus Therapeutics by 75.0% in the 2nd quarter. Strs Ohio now owns 18,900 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 8,100 shares during the period. Quantitative Systematic Strategies LLC increased its stake in Amicus Therapeutics by 138.3% in the 2nd quarter. Quantitative Systematic Strategies LLC now owns 66,532 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 38,608 shares during the period. Finally, Rothschild & Co. Asset Management US Inc. increased its stake in Amicus Therapeutics by 2.9% in the 2nd quarter. Rothschild & Co. Asset Management US Inc. now owns 1,534,423 shares of the biopharmaceutical company’s stock worth $19,150,000 after purchasing an additional 43,483 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

See Also: What is meant by holder of record?

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.